Clinical Trial Update: Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of the selective JAK1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to meth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Filgotinib (filgotinib)

Snippet

Sponsor: Atsushi Kawakami | Conditions: Rheumatoid Arthritis, JAK Inhibitor | Phase 3 | Status: UNKNOWN